

ondine



For Immediate Release

Ondine Announces Successful Outcome from Periowave™ Multi-Center Gum Disease Trial

Vancouver, Canada – May 7, 2008 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced outcomes of its Canadian Multi-Center Gum Disease Trial using the Periowave™ photodisinfection system for treatment of chronic adult periodontitis.

This trial was the Company's fourth and largest study to date, comparing its Periowave™ Photodisinfection System to the gold standard of Scaling and Root Planing (SRP) alone for the treatment of periodontal disease. Two formats of laser system were used in this study: the first a lower-power laser unit and the second a higher-power unit commercially available in the Periowave™ photodisinfection system. Results showed that lower-power lasers were not able to achieve statistical or clinical significance on any endpoint. Only the commercially available system met the primary endpoint (improvement in clinical attachment level, CAL, $p=0.003$) and secondary endpoint (improvement in pocket depth, PD, $p=0.01$). For all pockets averaged together, improvement in CAL in the Periowave™ arm was 154% of SRP alone and improvement in pocket depth was 138% of SRP alone.

“The trial results confirm the positive in-field experiences of clinicians using the Periowave™ system in Canada and the European Union. Periowave™ represents a significant, non-antibiotic, minimally-invasive adjunctive approach to the treatment of gum disease,” stated Carolyn Cross, Ondine's President and CEO. “In addition to the latest clinical efficacy data, there have been no reported product-related adverse events. The Company intends to submit detailed results of this study to the FDA as part of its ongoing discussions seeking marketing approval for Periowave™ in the U.S.”

Ondine's Periowave™ Photodisinfection System for chronic adult periodontitis has now been evaluated in four clinical trials involving approximately 300 patients and nearly 8,700 disease sites. The technology has consistently demonstrated efficacy and safety as an adjunctive therapy to SRP in the treatment of chronic adult periodontal disease.

About The Canadian Multi-Center Trial

The Canadian Multi-Center Trial was a prospective, randomized, examiner-blinded study that included 121 patients and 4,500 defect treatment sites. Fifty-eight patients were included in the Periowave™ treatment arm and sixty-three patients were included in the control arm.

The study was conducted at the University of Western Ontario, the University of Alberta, the University of Saskatchewan, and at a large private periodontal clinic in Toronto. More information about this trial can be found on the ClinicalTrials.gov website: <http://clinicaltrials.gov/ct2/show/NCT00297531>

About Periowave™

Periowave™ is a photodisinfection system commercialized by Ondine that utilizes low-intensity lasers and microbiological stains to target and destroy microbial pathogens and reduce the symptoms of disease. The photodisinfection technology was developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business plc, University College London. Periowave™ is currently approved in Canada and the European Union for several oral indications. Additional information about Periowave™ is available at www.periowave.com

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION please contact:

Carolyn Cross
President and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555
ccross@ondinebiopharma.com

Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269
cbessant@equicomgroup.com

Canaccord Adams Ltd
Nominated Adviser &
Broker
Neil Johnson /
Ryan Gaffney
+4420 7050 6500